(Q33944741)

30 July 2017

title

Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications (English)

1 reference

30 July 2017

1 reference

Stephan Kruck

0 references

Arnulf Stenzl

1 reference

30 July 2017

Joerg Hennenlotter

1 reference

30 July 2017

Ulrich Vogel

1 reference

30 July 2017

David Schilling

1 reference

30 July 2017

Georgios Gakis

1 reference

30 July 2017

Joachim Hevler

1 reference

30 July 2017

Ursula Kuehs

1 reference

30 July 2017

Christian Schwentner

1 reference

30 July 2017

publication date

28 June 2011

1 reference

30 July 2017

1 reference

30 July 2017

volume

109

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

634-638

1 reference

Renal cell carcinoma guideline

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

An update on the medical therapy of advanced metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

The proliferation marker thymidine kinase 1 level is high in normal kidney tubule cells compared to other normal and malignant renal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

Specific recognition of cytosolic thymidine kinase in the human lung tumor by monoclonal antibodies raised against recombinant human thymidine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

Investigation on cell proliferation with a new antibody against thymidine kinase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10392.X

10.1111/J.1464-410X.2011.10392.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference